Shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) have been assigned a consensus recommendation of “Buy” from the twelve ratings firms that are currently covering the stock. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $43.57.

A number of brokerages have issued reports on ZLTQ. Canaccord Genuity increased their price objective on shares of Zeltiq Aesthetics from $41.00 to $45.00 and gave the company a “buy” rating in a report on Thursday. Zacks Investment Research lowered shares of Zeltiq Aesthetics from a “strong-buy” rating to a “hold” rating in a report on Saturday. Northcoast Research reaffirmed a “buy” rating on shares of Zeltiq Aesthetics in a report on Tuesday, November 8th. Maxim Group increased their price objective on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a report on Tuesday, August 9th. Finally, Brean Capital set a $39.00 price objective on shares of Zeltiq Aesthetics and gave the company a “buy” rating in a report on Tuesday, August 9th.

In other Zeltiq Aesthetics news, insider Keith J. Sullivan sold 8,000 shares of Zeltiq Aesthetics stock in a transaction on Friday, November 4th. The shares were sold at an average price of $33.01, for a total transaction of $264,080.00. Following the completion of the transaction, the insider now directly owns 82,023 shares of the company’s stock, valued at $2,707,579.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Bradley Hauser sold 3,000 shares of Zeltiq Aesthetics stock in a transaction on Monday, September 12th. The stock was sold at an average price of $37.33, for a total transaction of $111,990.00. Following the transaction, the vice president now directly owns 46,240 shares of the company’s stock, valued at $1,726,139.20. The disclosure for this sale can be found here. Company insiders own 15.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Louisiana State Employees Retirement System raised its position in Zeltiq Aesthetics by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 14,300 shares of the company’s stock valued at $391,000 after buying an additional 100 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Zeltiq Aesthetics by 2.1% in the third quarter. PNC Financial Services Group Inc. now owns 5,218 shares of the company’s stock valued at $205,000 after buying an additional 107 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in Zeltiq Aesthetics by 1.2% in the third quarter. Municipal Employees Retirement System of Michigan now owns 9,910 shares of the company’s stock valued at $389,000 after buying an additional 120 shares during the period. PineBridge Investments L.P. increased its stake in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock valued at $112,000 after buying an additional 193 shares during the period. Finally, New York State Teachers Retirement System increased its stake in Zeltiq Aesthetics by 0.4% in the second quarter. New York State Teachers Retirement System now owns 47,852 shares of the company’s stock valued at $1,308,000 after buying an additional 200 shares during the period.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.41 on Thursday. The company has a market capitalization of $1.57 billion, a price-to-earnings ratio of 50.85 and a beta of 0.89. The company’s 50-day moving average is $37.67 and its 200-day moving average is $33.39. Zeltiq Aesthetics has a 12-month low of $18.41 and a 12-month high of $41.48.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its earnings results on Wednesday, November 9th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.04. Zeltiq Aesthetics had a net margin of 9.48% and a negative return on equity of 6.45%. The company had revenue of $95.20 million for the quarter, compared to analysts’ expectations of $90.84 million. During the same quarter last year, the business earned $0.05 EPS. The firm’s revenue was up 55.6% compared to the same quarter last year. Analysts predict that Zeltiq Aesthetics will post ($0.08) EPS for the current year.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.